Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab)

John P Leonard; Brian K Link

doi:10.1053/sonc.2002.30149

Back

Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab)

Journal article

Peer reviewed

Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab)

John P Leonard and Brian K Link

Seminars in oncology, Vol.29(1 Suppl 2), pp.81-86

02/2002

DOI: 10.1053/sonc.2002.30149

PMID: 11842393

View Online

Abstract

Clinical activity of anti-CD20 monoclonal antibodies both in the unlabeled (rituximab [Rituxan; Genentech, Inc, South San Francisco, CA, and IDEC Pharmaceuticals, San Diego, CA]) and radiolabeled forms, as well as radioimmunoconjugates targeting other antigens, has resulted in the exploration of alternative targets for immunotherapeutic strategies in lymphoma. We report on the rationale for and initial efforts in the development of two unlabeled, humanized monoclonal antibodies directed against molecules commonly expressed in B-cell malignancies. hLL2 (epratuzumab; Immunomedics, Inc, Morris Plains, NJ) binds to the CD22 antigen, while Hu1D10 (apolizumab; Protein Design Labs, Inc, Fremont, CA) reacts with a polymorphism on the HLA-DR beta chain. Preclinical studies and early clinical evaluations suggest that these agents have a potential role as novel therapeutic targets for lymphoma with acceptable toxicity profiles. Further efforts will explore optimal clinical settings for their use, as well as define treatment regimens either as single agents or in combination with chemotherapy or other biologics.

Immunotherapy - methods

HLA-DR Antigens

Cell Adhesion Molecules

Humans

Antineoplastic Agents - therapeutic use

Clinical Trials as Topic

Antibodies, Monoclonal

Antibodies, Monoclonal, Humanized

Antigens, Differentiation, B-Lymphocyte

Lectins

Sialic Acid Binding Ig-like Lectin 2

Antigens, CD

Lymphoma, Non-Hodgkin - drug therapy

Details

Title: Subtitle: Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab)
Creators: John P Leonard - Center for Lymphoma and Myeloma and Division of Hematology/Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
Brian K Link
Resource Type: Journal article
Publication Details: Seminars in oncology, Vol.29(1 Suppl 2), pp.81-86
DOI: 10.1053/sonc.2002.30149
PMID: 11842393
ISSN: 0093-7754
eISSN: 1532-8708
Language: English
Date published: 02/2002
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984094586302771

Metrics

9 Record Views

64 Times Cited - Web of Science